Sarah B. Goldberg, MD, MPH

Articles

Dr. Goldberg on Immune/Targeted Therapy Combos in Oncogene-Driven Lung Cancer

August 3rd 2019

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

Dr. Goldberg Discusses the Diagnosis of Mesothelioma

April 2nd 2019

Sarah B. Goldberg, MD, MPH, assistant professor of medicine, Yale School of Medicine and Yale Cancer Center, discusses the diagnosis of patients with mesothelioma.

Dr. Goldberg on Managing CNS Metastases in Oncogene-Driven NSCLC

February 21st 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses strategies for managing central nervous system metastases in patients with oncogene-driven non–small cell lung cancer.

Dr. Goldberg on Treatment Strategies for CNS Metastases

February 6th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses treatment strategies for patients with non–small cell lung cancer that develop central nervous system metastases.

Dr. Goldberg Discusses Treatment Approaches for Mesothelioma

January 27th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLC

April 12th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.

Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLC

March 30th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses options for patients with non

Dr. Goldberg on Resistance to Osimertinib for NSCLC

March 26th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses resistance to first- or second-line osimertinib (Tagrisso) for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Goldberg Discusses Osimertinib in NSCLC

March 23rd 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non–small cell lung cancer.

Dr. Goldberg Discusses Resistance to EGFR TKI Therapy in NSCLC

March 8th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.

x